AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02744924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: The intervention is comprised of 5 steps:~1. Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals~2. Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails~3. Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.~4. Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.~5. Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project
Study NCT02879838 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Biobank. Analysis of cytokines and DNA polymorphisms
Study NCT06015776 — intervention group
Intervention type: OTHER
Intervention: Gender
Description: Differences between men and women will be observed
Study NCT04454671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous neuromodulation (NMPE)
Description: It is a technique based on electrical stimulation of a peripheral nerve through an ultrasound-guided needle or a muscle at a motor site. The stimulation is performed with low or medium frequency currents in which a sensory and / or motor response is sought by stimulating the peripheral nerve
Study NCT04454671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound-guided dry needling
Description: Dry needling technique under ultrasound imaging in order to ensure accurate placement of the needle for optimum results.
Study NCT03715634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INDV-6200
Description: Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
Study NCT03715634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
Study NCT03715634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL Buprenorphine
Description: All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability
Study NCT03715634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SL Buprenorphine
Description: All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability
Study NCT03715634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalorex
Description: Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
Study NCT03715634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nalorex
Description: Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
Study NCT01545999 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain Stimulation via Transcranial Magnetic Stimulation
Description: PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task.
Study NCT01545999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain Stimulation via Transcranial Magnetic Stimulation
Description: PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task.
Study NCT02905877 — intervention group
Intervention type: OTHER
Intervention: Behavioural study
Description: reaching studies and other behavioural studies.
Study NCT02440672 — intervention group
Intervention type: DEVICE
Intervention: JOURNEY™ II CR Total Knee System (J II CR TKS)
Description: TKA with Journey II CR Total Knee System
Study NCT03640754 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF injected subcutaneously 3 times (Days 0, 28, 56)
Study NCT03640754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Saline
Description: Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)
Study NCT04682639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive etrasimod matching placebo tablet by mouth, once daily during the 24-week Double-Blind Treatment Period.
Study NCT04682639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etrasimod
Description: Participants will receive etrasimod tablet by mouth, once daily during the 28-week Extension Treatment Period.
Study NCT05329402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable Powered Articulating Endoscopic Linear Cutter Stapler
Description: Using the Disposable Powered Articulating Endoscopic Linear Cutter Stapler according to routine treatment
Study NCT01383954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diclofenac Gel
Description: Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
Study NCT04144387 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myelogram
Description: Two additional myelograms will be performed comparing to standard of care.
Study NCT00411762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT00411762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHY906
Study NCT05329402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ECHELON Flex Powered Articulating Endoscopic Linear Cutters
Description: Using the ECHELON Flex Powered Articulating Endoscopic Linear Cutters according to routine treatment
Study NCT02313077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-filo
Description: One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
Study NCT04793828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Velibra
Description: Velibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content.
Study NCT01396161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
Study NCT01396161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
Study NCT01396161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157 or Placebo
Description: One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
Study NCT00997672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
Study NCT00997672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00597727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut SLIT
Description: Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
Study NCT00597727 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Peanut SLIT
Description: Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
Study NCT00597727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SLIT
Description: Liquid glycerin without peanut which are dosed under the tongue.
Study NCT02658500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant Formula
Study NCT00836641 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: prevenar
Description: 7-valent pneumococcal conjugate vaccine
Study NCT00725868 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data private hospitals, angioplasty, sampling of blood
Description: * Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency~* coronary angioplasty~* Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made
Study NCT00824200 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene \& non-pharmacological management of peripheral edema.
Study NCT00824200 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral
Description: Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene \& non-pharmacological management of peripheral edema.
Study NCT00824200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin (alpha-adrenergic antagonist medication)
Description: 0.4 mg given daily
Study NCT02658500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: breast milk
Study NCT00836641 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumovax
Description: 23 valent pneumococcal polysaccharide vaccine
Study NCT02632227 — intervention group
Intervention type: PROCEDURE
Intervention: TFU(transfontanel ultrasound)
Description: The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
Study NCT00817258 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Description: Cisplatin 40mg/m2,weekly
Study NCT00817258 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)
Description: 3D-CRT or IMRT
Study NCT00824200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: tamsulosin placebo
Study NCT00824200 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo behavioral intervention
Study NCT01057316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula PTX Stent - Dose 1
Description: Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
Study NCT01057316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula PTX Stent - Dose 2
Description: Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
Study NCT03054935 — intervention group
Intervention type: OTHER
Intervention: Indirect Calorimetry
Description: Measurement of resting energy expenditure
Study NCT02836704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution~Route of administration: subcutaneous injection
Study NCT02836704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form: solution~Route of administration: subcutaneous injection
Study NCT02836704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form: table or capsule~Route of administration: oral administration
Study NCT03356002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan System
Description: Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure
Study NCT03356002 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-Scan System
Description: Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~1. To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~2. To evaluate the safety of the C-Scan Capsule System procedure
Study NCT02836704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Pharmaceutical form: table or capsule~Route of administration: oral administration
Study NCT02836704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acarbose
Description: Pharmaceutical form: table or capsule~Route of administration: oral administration
Study NCT02836704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acarbose
Description: Pharmaceutical form: table or capsule~Route of administration: oral administration
Study NCT02313077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26. ZEBOV
Description: One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
Study NCT03111498 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: practice-based training programme (one-to-one teaching)
Description: practice-based training programme (one-to-one teaching) for conducting VAD
Study NCT02313077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
Study NCT03214198 — intervention group
Intervention type: DRUG
Intervention: Vonoprazan
Description: Vonoprazan tablets
Study NCT01080209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimo PS DDS®
Description: Patients who received Brimo PS DDS® intravitreal implant in a previous study.
Study NCT01080209 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients who recieved sham in a previous study.
Study NCT01558245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tissue kallikrein
Description: Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
Study NCT01544153 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WEB
Description: Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
Study NCT02659826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anodal tsDCS
Description: Transcutaneous spinal cord stimulation will be delivered through a direct current (DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (anode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 milliampere (mA), fade in and fade out of 10 seconds, during 20 minutes.
Study NCT02659826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cathodal tsDCS
Description: Transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (cathode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during 20 minutes.
Study NCT02659826 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tsDCS
Description: sham transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The electrode anode will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during only 30 seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus, early sensations (eg. mild to moderate tingling or itch) on stimulation site will be experienced without inducing any modulatory effects.
Study NCT02659826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training
Description: It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
Study NCT01544153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB
Description: Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
Study NCT02659826 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gait training
Description: It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
Study NCT02659826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency rTMS
Description: Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20 hertz (Hz), 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28 seconds, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
Study NCT02659826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS
Description: Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed.
Study NCT02659826 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left primary motor area. After each rTMS session, presence of adverse effects will be computed.